Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease.

ABSTRACT: Early diagnosis of late-onset Alzheimer's disease (AD) by peripheral biomarkers remains a challenge; many have been proposed, but none have been evaluated in a prospective manner. CLUSTERIN (CLU), a chaperone protein expressed in the brain and found in relatively high concentrations in plasma, is a promising candidate. CLU contributes to the elimination of β-amyloid (Aβ), which is associated to neurofibrillary tangles and to the genetic risk for AD. We performed a longitudinal measurement of CLU in the brain and the plasma in 3xTgAD mice. Assessment of CLU was also conducted in 12-month-old TgF344-AD rats. In humans, brain CLU was measured in non-demented and in AD subjects. The plasma CLU was longitudinally measured in four cohorts defined as healthy controls that remained stable, healthy

SUBMITTER: Tournier BB 

PROVIDER: S-EPMC11835443 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature